Corporate Overview
Founded in 1993 by Dr. Robert Foster, Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. The Company is focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential will exceed $4 billion annually in sales for calcineurin inhibitors such as voclosporin by 2010.Voclosporin is a next generation calcineurin inhibitor, which recently completed a Phase 2b North American trial for the prevention of kidney rejection following transplantation. An extension to the Phase 2b trial and a combined Phase 3 European/Canadian trial for the treatment of moderate to severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently conducting three separate Phase 2/3 pivotal trials investigating voclosporin (referred to as LX211 by Lux) for the treatment of uveitis. Atrium Medical Corporation, another one of our partners, recently received approval from the Belgian Competent Authority to investigate voclosporin as the drug utilized in the CINATRA TM Drug Coated Coronary Stent system.
Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA".
Last updated May 30, 2008